Graphical human insulin time-activity profiles using standardized definitions.

The purpose of this study was to (1) develop consistent definitions to report time-activity profiles of insulin formulations, (2) determine human insulin time-activity profiles based on all available pharmacokinetic studies of biosynthetic human insulin rDNA(E. coli) (Humulin), and (3) create graphs that accurately and usefully represent human insulin time-activity profiles (TAPs). Standard definitions of onset, peak, duration, and time of 50% maximal activity were developed for human insulin. Results from all pharmacokinetic and pharmacodynamic studies available on human insulin from searches of both published literature and unpublished work were analyzed by these standard methods. Data obtained using these definitions were used to construct diagrams of the time-activity relationships for each formulation. Sixty-three insulin tests utilizing a variety of methodologies and data analysis techniques were located. Time-activity curves generated by application of standardized definitions varied depending on methodology, and on whether glucose, insulin and/or glucose infusion rates were used as the measure of insulin activity. A method of standard analysis is required for evaluating insulin pharmacokinetic studies due to the wide variation in design of these studies. Graphic representation of ranges obtained by standard analysis of onset, peak, duration, and 50% maximal activity increase the information transmitted when compared to currently used tables of time-activity data. The time of 50% maximal activity during increasing and decreasing phases may be a better marker of clinically significant activity than the classically defined parameters of onset and duration.

[1]  R. Bilous,et al.  Biosynthetic Human Insulin: Effect in Healthy Men on Plasma Glucose and Non-Esterified Fatty Acids in Comparison with Highly Purified Pork Insulin , 1981, Diabetes Care.

[2]  F. Enzmann,et al.  Comparison of Biosynthetic Human Insulin and Pork Insulin in the Gerritzen Test , 1981, Diabetes Care.

[3]  L Heinemann,et al.  The Action Profiles of Human NPH Insulin Preparations , 1989, Diabetic medicine : a journal of the British Diabetic Association.

[4]  A. Wright,et al.  Part 1 of a new educational series on research (a) improvement in NIDD patients poorly controlled on oral hypoglycaemic agents following transfer to insulin , 1987 .

[5]  R. Bilous,et al.  Plasma Insulin and C-Peptide After Subcutaneous and Intravenous Administration of Human Insulin (recombinant DNA) and Purified Porcine Insulin in Healthy Men , 1982, Diabetes Care.

[6]  R. Bilous,et al.  HUMAN INSULIN PRODUCED BY RECOMBINANT DNA TECHNOLOGY: SAFETY AND HYPOGLYCÆMIC POTENCY IN HEALTHY MEN , 1980, The Lancet.

[7]  P. Reichard,et al.  The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. , 1993, The New England journal of medicine.

[8]  van der Veen Ea,et al.  Absorption kinetics and action profiles of intermediate acting human insulins. , 1987 .

[9]  J. B. Collip,et al.  Pancreatic extracts in the treatment of diabetes mellitus: preliminary report. 1922. , 1991, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[10]  K. Drejer.  The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. , 1992, Diabetes/metabolism reviews.

[11]  J. Pickup.  Preliminary Evaluation of a Skin Conductance Meter for Detecting Hypoglycemia in Diabetic Patients , 1982, Diabetes Care.

[12]  P. Brunetti,et al.  Kinetics and Metabolic Activity of Biosynthetic NPH Insulin Evaluated by the Glucose Clamp Technique , 1984, Diabetes Care.

[13]  P. Bottermann,et al.  Pharmacokinetics of Biosynthetic Human Insulin and Characteristics of Its Effect , 1981, Diabetes Care.

[14]  D. Howey,et al.  Establishment of Time-Action Profiles for Regular and NPH Insulin Using Pharmacodynamic Modeling , 1994, Diabetes Care.

[15]  J. Thijssen,et al.  Injection Site Effects on the Pharmacokinetics and Glucodynamics of Insulin Lispro and Regular Insulin , 1996, Diabetes Care.

[16]  S. Fineberg,et al.  The Plasma Glucose Response of Normal Fasting Subjects to Neutral Regular and NPH Biosynthetic Human and Purified Pork Insulins , 1981, Diabetes Care.

[17]  D R Owens,et al.  Absorption Kinetics and Action Profiles of Subcutaneously Administered Insulin Analogues (AspB9GluB27, AspB10, AspB28) in Healthy Subjects , 1991, Diabetes Care.

[18]  L Heinemann,et al.  Pharmacokinetics and pharmacodynamics of subcutaneously administered U40 and U100 formulations of regular human insulin. , 1992, Diabete & metabolisme.

[19]  D. Howey,et al.  [Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human Insulin , 1994, Diabetes.

[20]  J. Davidson,et al.  Factors Influencing the Absorption, Serum Insulin Concentration, and Blood Glucose Responses After Injections of Regular Insulin and Various Insulin Mixtures , 1981, Diabetes Care.

[21]  M. Antsiferov,et al.  Exercise Augments the Absorption of Isophane (NPH) Insulin , 1989, Diabetic medicine : a journal of the British Diabetic Association.

[22]  P. Brunetti,et al.  Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM RID=""ID="" Abbreviations: HI, Human insulin; MI, monomeric insulin; NEFA, non-esterified fatty acid; HGO, hepatic glucose production rate; , 1994 .

[23]  A. Marble.  INSULIN IN THE TREATMENT OF DIABETES. , 1963, The Journal-lancet.

[24]  C H Best,et al.  Pancreatic Extracts in The Treatment of Diabetes Mellitus , 1956, Diabetes.

[25]  J. Pickup,et al.  Textbook of Diabetes , 1991 .

[26]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[27]  Comparison of subcutaneously administered soluble insulin and des-(B26-B30)-insulin-B25-amide in rabbit, pig and healthy man. , 1992, Diabetes research and clinical practice.

[28]  F. Mair,et al.  Pharmacokinetics of Human Insulin Zinc Suspension (Recombinant DNA) in Normal Man: A Comparison with Porcine Insulin Zinc Suspension , 1984, Diabetic medicine : a journal of the British Diabetic Association.

[29]  K. Alberti,et al.  A comparison of the pharmacokinetics and metabolic effects of human regular and NPH insulin mixtures. , 1991, Diabetes research and clinical practice.

[30]  G. Nell,et al.  Pharmacodynamics of Human Insulin (recombinant DNA)—Regular, NPH, and Mixtures—Obtained by the Gerritzen Method in Healthy Volunteers , 1982, Diabetes Care.

[31]  L. Heinemann,et al.  PHARMACOKINETICS AND GLUCODYNAMICS OF INSULIN LISPRO , 1998 .

[32]  H. Rifkin,et al.  Ellenberg and Rifkinʼs Diabetes Mellitus: Theory and Practice , 1992 .

[33]  G. Sonnenberg,et al.  Absorption Kinetics of Semisynthetic Human Insulin and Biosynthetic (recombinant DNA)Human Insulin , 1982, Diabetes Care.

[34]  L. Sestoft,et al.  The Absorption of Subcutaneously Injected Short-Acting Soluble Insulin: Influence of Injection Technique and Concentration , 1983, Diabetes Care.

[35]  T. Chalmers,et al.  Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes , 1993, The Lancet.

[36]  K. Kosaka,et al.  Clinical Pharmacology of Human Insulin of Recombinant DNA Origin in Healthy Volunteers , 1982, Diabetes Care.

[37]  H. Velcovsky,et al.  Biologic and Immunologic in Vivo and In Vitro Studies with Biosynthetic Human Insulin , 1981, Diabetes Care.

[38]  P. Bottermann,et al.  Insulin Concentrations and Time-Action Profiles of Three Different Intermediate-acting Insulin Preparations in Nondiabetic Volunteers Under Glucose-controlled Glucose Infusion Technique , 1982, Diabetes Care.